Genmab — Juli 2018
-
Trial of Dara in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) was withdrawn, it was supposed to start this month
https://clinicaltrials.gov/ct2/history/NCT03207542?A=6&B=7&C=merged -
Danske købere er på ferie. Næst største køber efter A/B er svenske Avanza med hele 3 stk. aktier.
-
Altså netto efter køb af 10 stk og salg af 7.
-
Ligner et fornuftigt luk. Det mener Avanza også - og har derfor købt et stk. ekstra aktie.
-
-
Kinase inhibitor advances in MM: predictive biomarkers & efficacy of daratumumab http://www.oncologytube.com/video/kinase-inhibitor-advances-in-mm-predictive-biomarkers-efficacy-of-daratumumab/10004733
-
Trial represents ‘bold move’ for treatment of newly diagnosed myeloma - https://www.healio.com/hematology-oncology/myeloma/news/online/{1ebabaf8-6883-4567-8253-bc4ce2e72ecf}/trial-represents-bold-move-for-treatment-of-newly-diagnosed-myeloma
-
from Seattle Genetics Q2 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=RssLanding&cat=news&id=2360357
-
Tisotumab Vedotin (TV) Program Activities
• Metastatic Cervical Cancer Trial Initiated: Seattle Genetics and Genmab initiated a phase 2 trial called innovaTV 204 in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. The trial will enroll approximately 100 patients and is intended to potentially support registration under the FDA's accelerated approval pathway. -
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind